Scancell Holdings updates on clinical trial of melanoma vaccine

Scancell Holdings said Tuesday it edged closer to completing clinical trials of a vaccine for the treatment of melanoma.

Scancell Holdings said Tuesday it edged closer to completing clinical trials of a vaccine for the treatment of melanoma.

The developer of therapeutic cancer vaccines recruited and treated the final patient in the second phase of tests for SCIB1, a DNA ImmunoBody injection.

The trial is being conducted in five UK centres in patients with Stage III/IV disease to assess the safety of the treatment and the immune response.

Patients are being treated with a 4.0mg dose of SCIB1, five times over six months.

Last month Scandell released findings from the first phase of the study which showed SCIB1 produced an immune response that may benefit patients with malignant melanoma.

At the same the group also announced approval from regulators to treat an extra group of patients with a higher 8.0mg dose of the vaccine.

"As expected, the recruitment of patients in the second part of the trial proceeded faster than recruitment for the first part of the trial, as we were not constrained by the cohort study design requiring sequential dose escalation, and there were more patients available with earlier stage disease," said Lindy Durrant, Joint Chief Executive Officer (CEO) of Scancell Holdings and Professor of Cancer Immunotherapy at Nottingham University.

"The recruitment and dosing of the final patient in part two gives us confidence that this phase of the study will be completed by the end of 2013, consistent with previous expectations."

Shares were down 0.59% to 42.25p at 9:19 Tuesday.

RD

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020

Most Popular

Why we won’t see a house-price crash in 2021
House prices

Why we won’t see a house-price crash in 2021

Lockdown sent house prices berserk as cooped up home-workers fled for bigger properties in the country. And while they won’t rise quite as much this y…
18 Jan 2021
The world’s fund managers are getting very bullish – be careful out there
Stockmarkets

The world’s fund managers are getting very bullish – be careful out there

The latest survey of fund managers shows them to be extremely bullish on all the same things. And that, says John Stepek, means the market is in dange…
21 Jan 2021
Prepare for the end of the epic bubble in US stocks
US stockmarkets

Prepare for the end of the epic bubble in US stocks

US stocks are as expensive as they’ve ever been. How can you prepare your portfolio for a bubble bursting?
18 Jan 2021